Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Global brain maintenance predicts well-preserved cognitive function: A pooled analysis of three longitudinal population-based Swedish cohorts.

Neurobiology of aging·2026
Same author

Multimodal axes reveal individualized amyloid- <math><mi>β</mi></math> , tau, and neurodegeneration coupling in aging and Alzheimer's disease.

medRxiv : the preprint server for health sciences·2026
Same author

[Brain imaging in cognitive disorders - from diagnosis to treatment and monitoring].

Lakartidningen·2026
Same author

Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC.

The journal of prevention of Alzheimer's disease·2026
Same author

Co-pathologies and biological processes beyond amyloid-beta and tau in people with Alzheimer's disease: Evidence from clinical cohort studies.

Journal of internal medicine·2026
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Rosaleena Mohanty1, Sophia Wheatley1, Giulia Lorenzon1

  • 1Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

根据典型性和严重程度识别的阿尔茨海默病 (AD) 亚型显示出不同的神经成像模式和对治疗的反应. 了解这些亚型对于个性化的AD诊断和治疗至关重要.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经成像和神经科学 神经成像和神经科学
  • 生物标志物发现发现
  • 个性化医疗是个性化的医疗.

背景情况:

  • 阿尔茨海默病 (AD) 呈现出显著的生物学异质性,导致不同的亚型,如典型的AD,边缘主导,皮质主导和最小缩.
  • 之前的研究已经基于区域脆弱性,典型性和严重性对这种异质性进行了概念化.
  • 关于跨模式比较,共病学的作用,时间演变和AD亚型的治疗反应跟踪,仍然存在关键问题.

研究的目的:

  • 用典型性和严重性指标的组合来调查阿尔茨海默病 (AD) 亚型.
  • 在多种神经成像方式中比较AD亚型,包括MRI,FDG PET和tau PET.
  • 探索共病理和纵向变化对AD亚型及其对治疗的反应的影响.

主要方法:

  • 经过检查的AD亚型,以典型性 (中等时与新皮质比率) 和严重性 (全球生物标志物平均值) 定义.
  • 在多个国际队列中利用了关于缩 (MRI),低代谢 (FDG PET) 和病理 (tau PET) 的最新评论和新证据.
  • 讨论了与粉样β (Aβ),,神经退行,脑血管和α-synuclein病理学有关的发现.

主要成果:

  • 典型性和严重性在MRI,FDG PET和tau PET中有效地识别了AD亚型,但亚型无法在各种模式中一致转化.
  • 大脑血管共病症,特别是动脉样硬化,对缩和低代谢亚型产生了差异性影响,而α-synuclein没有.
  • 纵向分析显示,边缘主导和最小缩亚型随着时间的推移而趋同,女性显示较早的缩和白质异常.
  • 亚尔茨海默病亚型对多尼佩西尔治疗的反应有所差异,而最小的缩和皮质主导的亚型显示出更大的益处.

结论:

  • 典型性和严重性的结合为研究阿尔茨海默病 (AD) 中的神经生物学异质性的研究提供了一个框架.
  • 多模式和纵向亚尔茨海默病的亚型是推进个性化诊断,预后和治疗策略的必要条件.
  • 对阿尔茨海默症亚型的计算为更定制的治疗干预提供了途径.